3.2 Data mining
In current study, we selected reports containing products “lenvatinib”, “sorafenib”, “cabozantinib” and “regorafenib” as “primary suspect” for further study. Arbitrary drug names may be reported in the FAERS, therefore, the MICROMEDEX® (Index Nominum) was utilized as a dictionary for TKIs(Table 1). The suspected adverse events(AEs) were coded according to the Medical Dictionary for Regulatory Activities (MedDRA®). We grouped cardiac AEs in the MedDRA classification (version 25.1) that are related to the same medical condition.